Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials, Diabetes and Metabolism Journal (2019) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Patient assistance program, Novo Nordisk APC: Find a compounder, Alliance for Pharmacy Compounding (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Some weeks the scale does not move
For travel and on-the-go use, ODTs are the clear winner
building muscle at the gym is harder than it used to be
The blood pressure-lowering effect stems partly from weight loss itselfas your body weight decreases, your heart works less hard to circulate blood, and blood vessel function improves
